StreetInsider.com News Articles

Form 4 AGENUS INC For: Jun 12 Filed by: ARMEN GARO H

Tue, 16 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26651378.html

Form 4 AGENUS INC For: Jun 12 Filed by: ARMEN GARO H

Tue, 16 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26651378.html

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Tue, 02 Jun 2026 16:30:00 -0400

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:45 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2026 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:

Date:

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Tue, 02 Jun 2026 16:30:00 -0400

Webcast Information:

Date:

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Tue, 02 Jun 2026 16:30:00 -0400

Webcast Information:

Date:

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Tue, 02 Jun 2026 16:30:00 -0400

Webcast Information:

Date:

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Tue, 02 Jun 2026 16:30:00 -0400

Webcast Information:

Date:

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Tue, 02 Jun 2026 16:30:00 -0400

Webcast Information:

Date:

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Tue, 02 Jun 2026 16:30:00 -0400

Webcast Information:

Date:

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Tue, 02 Jun 2026 16:30:00 -0400

Webcast Information:

Date:

Form 4 AGENUS INC For: May 29 Filed by: ARMEN GARO H

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586845.html

Form 4 AGENUS INC For: May 29 Filed by: ARMEN GARO H

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586845.html

Agenus reports AI analysis shows improved response rates for cancer treatment

Thu, 21 May 2026 17:00:46 -0400

Agenus Inc. (NASDAQ: AGEN) announced retrospective data showing that artificial intelligence analysis of routine tumor images identified patients more likely to respond to its experimental cancer treatment combination.

The analysis used Noetik's TARIO-2 platform to examine standard pathology images from 113 patients treated with botensilimab plus balstilimab in a Phase 1b trial. The AI system analyzed spatial tumor microenvironment patterns from hematoxylin and eosin stained tissue samples taken before treatment.

In patients with microsatellite stable metastatic colorectal cancer without active liver metastases, the AI-identified subgroup showed a 64% response rate compared to 9% in the remaining patients. The AI-identified group also demonstrated

Agenus reports AI analysis shows improved response rates for cancer treatment

Thu, 21 May 2026 17:00:46 -0400

Agenus reports AI analysis shows improved response rates for cancer treatment

Thu, 21 May 2026 17:00:46 -0400

Agenus reports AI analysis shows improved response rates for cancer treatment

Thu, 21 May 2026 17:00:46 -0400

Agenus reports melanoma trial data for drug combination BOT+BAL

Thu, 21 May 2026 17:00:39 -0400

Agenus Inc. (NASDAQ: AGEN) presented Phase 2 trial data for its drug combination botensilimab and balstilimab in patients with advanced melanoma that had resisted prior checkpoint therapy at the American Society of Clinical Oncology Annual Meeting.

The study included 36 heavily pretreated patients with advanced cutaneous melanoma whose disease had resisted prior anti-PD-(L)1 therapy. The trial showed a median overall survival of 16.6 months, with 42% of patients alive at two years. The confirmed objective response rate was 22%.